Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Authors: Bharadwaj S; Stanford University School of Medicine, Stanford, California, USA., Lau E; Stanford University School of Medicine, Stanford, California, USA., Hamilton MP; Stanford University School of Medicine, Stanford, California, USA., Goyal A; Stanford University School of Medicine, Stanford, California, USA., Srinagesh H; Stanford University School of Medicine, Stanford, California, USA., Jensen A; Stanford University School of Medicine, Stanford, California, USA., Lee D; Stanford University School of Medicine, Stanford, California, USA., Mallampet J; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA., Elkordy S; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA., Syal S; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA., Patil S; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA., Latchford T; Stanford University School of Medicine, Stanford, California, USA., Sahaf B; Cancer Institute, Stanford University School of Medicine, Palo Alto, California, USA., Arai S; Stanford University School of Medicine, Stanford, California, USA., Johnston LJ; Stanford University School of Medicine, Stanford, California, USA., Lowsky R; Stanford University School of Medicine, Stanford, California, USA., Negrin R; Stanford University, Stanford, California, USA., Rezvani AR; Stanford University School of Medicine, Stanford, California, USA., Shizuru J; Stanford Medicine, Palo Alto, California, USA., Meyer EH; Stanford University School of Medicine, Stanford, California, USA., Shiraz P; Stanford University School of Medicine, Stanford, California, USA., Mikkilineni L; Stanford University School of Medicine, Stanford, California, USA., Weng WK; Stanford University School of Medicine, Stanford, California, USA., Smith M; Stanford University School of Medicine, Stanford, California, USA., Sidana S; Stanford University School of Medicine, Stanford, California, USA., Muffly L; Stanford University, Palo Alto, California, USA., Maecker HT; Stanford University, Stanford, California, USA., Frank MJ; Stanford University School of Medicine, Stanford, California, USA., Mackall C; Stanford University, Stanford, California, USA., Miklos D; Stanford University, Stanford, California, USA., Dahiya S; Stanford University School of Medicine, Stanford, California, USA sdahiya@stanford.edu.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 01; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 01.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2024-008975